Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).

Timeline

Start

2023-04-28

Primary completion

2024-10-31

Completion

2024-10-31

Outcome

Outcome not reported

Stopped: “The parent study 20170104 was terminated due to the study meeting a prespecified futility rule. Consequently, this study was terminated.”

Drugs

Indications